Endocrine Abstracts

Background: Pulmonary carcinoid (PC) tumors represent approximately 25% of neuroendocrine tumors (NETs) and about 2% of all lung cancers. Despite the relative prevalence of PCs compared to all NETs, there is only one FDA indicated therapy (everolimus). Since regulatory approvals stem from publications that are often initially presented at scientific meetings, we sought to determine the frequency of presentations including PCs at two major international NET and lung cancer meet...